<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00846482</url>
  </required_header>
  <id_info>
    <org_study_id>07-10-376</org_study_id>
    <nct_id>NCT00846482</nct_id>
  </id_info>
  <brief_title>Exploratory Study Of The ERCC-1 Gene</brief_title>
  <official_title>Exploratory Study Of The ERCC-1 Gene Expression In Colorectal Cancer Cell Lines And In Patients With Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Albert Einstein College of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Albert Einstein College of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is for patients with advanced or stage II and III colon or rectal cancer. The&#xD;
      primary purpose of this research study is to determine if a particular protein in the&#xD;
      patient's blood will change when they receive treatment with a drug called oxaliplatin, which&#xD;
      is used to treat the colon or rectal cancer. This protein is called ERCC-1. It is thought&#xD;
      that the amount of this protein in the blood could influence the manner in which the patient&#xD;
      responds to oxaliplatin.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">December 2018</completion_date>
  <primary_completion_date type="Actual">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients With Excision Repair Cross-complementing Group-1 (ERCC1) Protein Change When Treated With Oxaliplatin</measure>
    <time_frame>Change over 1 treatment cycle, up to 4 weeks</time_frame>
    <description>ERCC was measured at the expression level, by RT-PCR and Western Blotting from peripheral blood mononuclear cells</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine Extent of ERCC Polymorphism and Its Relationship to Change in Its Level</measure>
    <time_frame>Change over 1 treatment cycle, up to 4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Colon Cancer</condition>
  <condition>Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>Resected or metastatic CRC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients with advanced or stage II or III colorectal cancer being treated with oxaliplatin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>Oxaliplatin will be administered once every 2 or 3 weeks</description>
    <arm_group_label>Resected or metastatic CRC</arm_group_label>
    <other_name>Eloxatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed diagnosis of colorectal cancer.&#xD;
&#xD;
          -  ECOG Performance Status 0-2 (Appendix A).&#xD;
&#xD;
          -  Patient is a candidate for oxaliplatin based therapy either in the adjuvant or in the&#xD;
             metastatic setting.&#xD;
&#xD;
          -  Consent to donate 4 tubes of PBMC of 7 ml of blood each.&#xD;
&#xD;
          -  Willing to consider additional post therapy tumor biopsy if applicable (refusal to&#xD;
             consent is not an exclusion criteria).&#xD;
&#xD;
          -  Adequate organ function as defined as:&#xD;
&#xD;
               -  Neutrophil count &gt; 1500/μl&#xD;
&#xD;
               -  Platelets &gt; 75,000/ μl&#xD;
&#xD;
               -  Hemoglobin &gt; 8 g/dl&#xD;
&#xD;
               -  Bilirubin &lt; 2.0 X upper limit of normal&#xD;
&#xD;
               -  Creatinine &lt; 2 mg% or calculated clearance &gt; 40 ml/mt&#xD;
&#xD;
          -  The patient must have signed a consent form approved by the Albert Einstein College of&#xD;
             Medicine Cancer Center CCI and Montefiore Medical Center IRB&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No other significant underlying medical condition that will, in the opinion of the&#xD;
             principal investigator or designees, make administration of oxaliplatin unusually&#xD;
             hazardous, such as significant hepatic, bone marrow and/or cardiac disease, requiring&#xD;
             active medical treatment.&#xD;
&#xD;
          -  Pregnant women or women of child bearing potential not practicing birth control or&#xD;
             sexually active males unwilling to practice contraception during the study.&#xD;
&#xD;
          -  Patients undergoing major surgical procedures (they will be delayed enrollment until&#xD;
             complete recovery from their surgery - 4 wk for major or 2 wk from minor surgery).&#xD;
&#xD;
          -  Patients with grade 2 neuropathy will not be eligible for the study.&#xD;
&#xD;
          -  The patient must not have received chemotherapy within 4 weeks of beginning&#xD;
             oxaliplatin treatment. At least 6 weeks must elapse if prior therapy included&#xD;
             mitomycin C or nitrosoureas. At least 2 weeks must have elapsed since the end of prior&#xD;
             palliative radiation therapy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>SANJAY GOEL, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Montefiore Medical Center/Albert Einstein College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Montefiore Medical Center - Weiler Campus</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center - Moses Campus</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Rao D, Mallick AB, Augustine T, Daroqui C, Jiffry J, Merla A, Chaudhary I, Seetharam R, Sood A, Gajavelli S, Aparo S, Rajdev L, Kaubisch A, Chuy J, Negassa A, Mariadason JM, Maitra R, Goel S. Excision repair cross-complementing group-1 (ERCC1) induction kinetics and polymorphism are markers of inferior outcome in patients with colorectal cancer treated with oxaliplatin. Oncotarget. 2019 Sep 17;10(53):5510-5522. doi: 10.18632/oncotarget.27140. eCollection 2019 Sep 17.</citation>
    <PMID>31565185</PMID>
  </reference>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>February 21, 2008</study_first_submitted>
  <study_first_submitted_qc>February 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 18, 2009</study_first_posted>
  <results_first_submitted>July 8, 2020</results_first_submitted>
  <results_first_submitted_qc>August 28, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 16, 2020</results_first_posted>
  <last_update_submitted>August 28, 2020</last_update_submitted>
  <last_update_submitted_qc>August 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Albert Einstein College of Medicine</investigator_affiliation>
    <investigator_full_name>Sanjay Goel</investigator_full_name>
    <investigator_title>Sanjay Goel, MD</investigator_title>
  </responsible_party>
  <keyword>Colorectal cancer</keyword>
  <keyword>Oxaliplatin</keyword>
  <keyword>ERCC-1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
    <mesh_term>Colonic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 4, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/82/NCT00846482/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 11, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/82/NCT00846482/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Resected or Metastatic CRC</title>
          <description>All patients with advanced or stage II or III colorectal cancer being treated with oxaliplatin&#xD;
Oxaliplatin: Oxaliplatin will be administered once every 2 or 3 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="64"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Fifty-four patients consented to the study and underwent serial blood sampling. Blood samples were collected from every patient for at least at two of the four prespecified time points.</population>
      <group_list>
        <group group_id="B1">
          <title>Resected or Metastatic CRC</title>
          <description>All patients with advanced or stage II or III colorectal cancer being treated with oxaliplatin&#xD;
Oxaliplatin: Oxaliplatin will be administered once every 2 or 3 weeks</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="54"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59" lower_limit="45" upper_limit="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unkown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Excision Repair Cross-complementing Group-1 (ERCC1) Protein Change When Treated With Oxaliplatin</title>
        <description>ERCC was measured at the expression level, by RT-PCR and Western Blotting from peripheral blood mononuclear cells</description>
        <time_frame>Change over 1 treatment cycle, up to 4 weeks</time_frame>
        <population>Any patient with CRC who received oxaliplatin</population>
        <group_list>
          <group group_id="O1">
            <title>All Patients With CRC</title>
            <description>All patients with advanced or stage II or III colorectal cancer being treated with oxaliplatin&#xD;
Oxaliplatin: Oxaliplatin will be administered once every 2 or 3 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Excision Repair Cross-complementing Group-1 (ERCC1) Protein Change When Treated With Oxaliplatin</title>
          <description>ERCC was measured at the expression level, by RT-PCR and Western Blotting from peripheral blood mononuclear cells</description>
          <population>Any patient with CRC who received oxaliplatin</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Determine Extent of ERCC Polymorphism and Its Relationship to Change in Its Level</title>
        <time_frame>Change over 1 treatment cycle, up to 4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Resected or Metastatic CRC</title>
            <description>All patients with advanced or stage II or III colorectal cancer being treated with oxaliplatin&#xD;
Oxaliplatin: Oxaliplatin will be administered once every 2 or 3 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Determine Extent of ERCC Polymorphism and Its Relationship to Change in Its Level</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CC genotype</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C/T genotype</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TT genotype</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>15 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Resected or Metastatic CRC</title>
          <description>All patients with advanced or stage II or III colorectal cancer being treated with oxaliplatin&#xD;
Oxaliplatin: Oxaliplatin will be administered once every 2 or 3 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Sanjay Goel</name_or_title>
      <organization>Montefiore Medical Center</organization>
      <phone>718-405-8404</phone>
      <email>sgoel@montefiore.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

